News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Could be worse ...
|
Followers
|
14
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
877
|
|
Created
|
07/18/14
|
Type
|
Free
|
| Moderators | |||
In 2011, Bedrocan BV, a Dutch company, was invited to Ottawa by Health Canada to comment on Canada’s new regulations for medicinal cannabis, the Marijuana for Medical Purposes Regulations (MMPR). Since the Netherlands has an established medicinal cannabis framework, we came away from this meeting with a sense that Canadian producers, patients, and healthcare professionals could benefit from the knowledge and experience Bedrocan BV had developed producing medicinal cannabis in Europe. We decided to look more closely into how we could provide Canadians access to high quality standardized medicinal cannabis. This led to our decision to work with Canadian management to establish a company in Canada to work under the newly established regulatory (MMPR) framework.
Bedrocan Canada is a joint venture between “Bedrocan BV” of the Netherlands and “Bedrocan Canada Inc”, a Canadian start-up with extensive knowledge and experience in the use of cannabis and cannabinoids in clinical practice.
Bedrocan Canada will contribute to the needs of Canadian patients by providing access to our varieties of standardized medicinal cannabis under a federally regulated environment, and by using science to address the real concerns of Canadian patients and health care practitioners. Bedrocan is about raising the expectations of what it means for cannabis to be truly “medicinal.” In this way, we will work together to bridge the gap with science to better serve the needs of patients and meet the regulatory demands of modern medicine.
For over 10 years, Bedrocan BV has worked with universities, industry, government, and NGO partners in the Netherlands and around the world to conduct the genetic, botanical, chemical, and social research necessary to help cannabis meet the regulatory demands of modern medicine.
Bedrocan BV has its roots in the North of the Netherlands, an area with a long history of agricultural achievements. Founded in 1984, we first specialized in the indoor, standardized growth of vegetables and herbs. It wasn’t until the late 1990′s when we began our first experiments in growing medicinal-grade cannabis under federal license.
In 1998, the Dutch Minister of Health, Welfare and Sport noticed patients purchasing cannabis from popularly known “coffeeshops”, where recreational use has been tolerated since the 1970′s. The Minister was concerned over the lack of quality control, and believed the “bar” atmosphere did not serve the medical needs of patients. In response, she proposed an official program whereby pharmaceutical-grade cannabis could be prescribed by doctors and dispensed through pharmacies.
In 2003, after a thorough screening by Dutch authorities, Bedrocan BV was contracted by the Dutch Ministry of Health’s newly-formed Office of Medicinal Cannabis (OMC) to produce different strains for patients and researchers. Other European countries soon created similar programs and requested a regular supply of cannabis from the only source in Europe that met the required medical standards.
Today, the Dutch government remains the only source in the world for medicinal-grade cannabis that is exported for patient use in full compliance with international laws and regulations.
Bedrocan is the sole supplier of marijuana to Germany, Finland, Italy and Norway.
Traded in Canada in the TSX-V market. Symbol BED.V
US grey market symbol BNRDF
https://bedrocan.ca/
Twitter Page
https://twitter.com/BedrocanCda
